New Sub-Analysis Of RE-LY Trial Examines Pradaxa In Patients With Atrial Fibrillation Undergoing Cardioversion
Links shared publicly online about this topic.
- 600total visits
New Sub-Analysis Of RE-LY Trial Examines Pradaxa In Patients With Atrial Fibrillation Undergoing Cardioversion
Results of a post-hoc analysis of the RE-LY® trial among patients with non-valvular atrial fibrillation (NVAF) undergoing cardioversion, a treatment to convert an abnormal heartbeat back to no
View full resource at medicalnewstoday.com
Tags: Heart Disease, Arrhythmia, Atrial Fibrillation
Most Recently Shared on January 6, 2011 at 7:05 pm By:
New Sub-Analysis Of RE-LY Trial Examines Pradaxa In Patients With Atrial Fibrillation Undergoing Cardioversion http://mnt.to/3PHb
Also Shared By:
New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion - Drugs.com MedNews
drugs.com — “Data from largest cardioversion analysis to date show low frequency of stroke and major bleeding with Pradaxa Results of a post-hoc analysis of the RE-LY trial” View full resource at drugs.com
Most Recently Shared on January 5, 2011 at 3:16 pm By:
Drugs and Devices OW OW Health
New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardiover... http://bit.ly/eT8aVr #drug
Advertisement
MNT Cardiovascular
@mnt_cardiovasc
New Sub-Analysis Of RE-LY Trial Examines Pradaxa In Patients With Atrial Fibrillation Undergoing Cardioversion http://mnt.to/3PHb
1 year ago...